drugset / Trial / NCT00431275

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

NCT00431275

Phase 1 Completed 85 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.

Timeline

Start
2006-06
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tremelimumab Monoclonal antibody 15 mg/kg Intravenous

Indications